Avatrombopag
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
- Avatrombopag
- Pharmacist Assessment Report
- Avatrombopag: thrombopoietin receptor agonist → Macrothrombocytopenia with mitral valve insufficiency (marcothrombocytopenia with mitral valve insufficiency)
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Avatrombopag: thrombopoietin receptor agonist → Macrothrombocytopenia with mitral valve insufficiency (marcothrombocytopenia with mitral valve insufficiency)
One-Sentence Summary
Avatrombopag is an oral thrombopoietin (TPO) receptor agonist. The TxGNN model predicts it may be relevant to marcothrombocytopenia with mitral valve insufficiency, but no clinical trials and no publications were found to support this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Macrothrombocytopenia with mitral valve insufficiency (marcothrombocytopenia with mitral valve insufficiency) |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Avatrombopag stimulates the thrombopoietin receptor (c-Mpl) on megakaryocytes, promoting their proliferation and platelet production. Detailed mechanism of action data was not available in the data compiled for this report, so this description relies on the drug’s generally known class pharmacology.
A mechanistic rationale exists only if the low platelet count results from reduced platelet production. Macrothrombocytopenia caused by structural or genetic platelet defects (for example MYH9-related or other inherited disorders) may not respond to TPO-receptor agonism. The mitral valve insufficiency component has no plausible link to the drug’s mechanism.
The TxGNN score is a model-derived prediction only. No trials or literature were available to confirm it.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 13313Q | Doptelet | Tablet 20 mg | Not recorded in the local data |
Safety Considerations
- Drug Interactions: 52 interacting drugs were identified in the interaction query. Examples of major-level interactions include fosphenytoin, carbamazepine, carfilzomib, dabrafenib, enzalutamide, fluconazole and imatinib. Moderate-level examples include clarithromycin, nitisinone, cobicistat, fosamprenavir, gemfibrozil, fenofibrate, apalutamide, atazanavir, amprenavir, boceprevir, ceritinib, delavirdine and idelalisib.
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting clinical trials or publications (evidence level L5). The mechanistic link is uncertain and depends on the cause of the low platelet count, and the mitral valve insufficiency component has no plausible link to the drug.
To proceed, the following is needed:
- Clinical or preclinical studies directly addressing this condition
- Confirmation of the underlying cause of thrombocytopenia (production defect vs. structural or functional defect)
- Detailed mechanism of action data
- Review of TGA Product Information warnings and contraindications, and a safety and interaction management plan
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.